Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
famitinib + SHR-A1811
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
Famitinib + SHR-A1811 is an investigational combination therapy being evaluated for the treatment of advanced breast cancer, particularly HR-positive/HER2-negative cases that have developed resistance to CDK4/6 inhibitors. Famitinib is a small-molecule multi-kinase inhibitor developed by Jiangsu Hengrui Pharmaceuticals that targets VEGFR2, PDGFR, and c-Kit, thereby inhibiting angiogenesis and tumor proliferation. SHR-A1811 is a next-generation antibody-drug conjugate (ADC) also developed by Jiangsu Hengrui Pharmaceuticals, consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload (SHR152852) via a cleavable linker. The combination is currently being studied in a Phase 3 trial led by Fudan University, focusing on the SNF4 molecular subtype of breast cancer to determine if the dual inhibition of angiogenic pathways and HER2-mediated signaling can improve outcomes in treatment-resistant populations.
- Other names
- famitinib + SHR-A1811
02
Targets
FGFR (FGFR family)AXL (AXL receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)VEGFR3 (Vascular endothelial growth factor receptor 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on famitinib + SHR-A1811.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on famitinib + SHR-A1811.